High-risk Myelodysplastic Syndrome

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

CT
Crossbow TherapeuticsMA - Cambridge
1 program
1
CBX-250Phase 11 trial
Active Trials
NCT06994676Recruiting72Est. Jun 2027

Trial Timeline

Clinical trial activity over time

2025
2026
2027
Crossbow TherapeuticsCBX-250

Clinical Trials (1)

Total enrollment: 72 patients across 1 trials

A Study of CBX-250 in Participants With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Start: Jul 2025Est. completion: Jun 202772 patients
Phase 1Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 72 patients
1 companies competing in this space